Drug intelligence / Profile preview

OriC322

Development stage: Preclinical
Lead developer: OriCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

OriC322 is a chimeric antigen receptor T cell (CAR-T) therapy under development by OriCell Therapeutics for the treatment of relapsed and refractory multiple myeloma. As a CAR-T therapy, it involves engineering a patient's own T cells to express a synthetic receptor that targets specific antigens on cancer cells, enabling the immune system to recognize and destroy malignant plasma cells characteristic of multiple myeloma. The product is currently in preclinical development[1][2].

Beyond the preview

Go deeper on OriC322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OriC322.

Explore the full profile